Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01177098




Registration number
NCT01177098
Ethics application status
Date submitted
4/08/2010
Date registered
6/08/2010
Date last updated
29/03/2013

Titles & IDs
Public title
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Scientific title
Secondary ID [1] 0 0
2010-021507-24
Secondary ID [2] 0 0
192024-050
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glaucoma 0 0
Ocular Hypertension 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - bimatoprost /timolol formulation A fixed combination ophthalmic solution
Treatment: Drugs - bimatoprost/timolol fixed combination ophthalmic solution

Experimental: bimatoprost/timolol formulation A - One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.

Active Comparator: bimatoprost/timolol fixed combination ophthalmic solution - One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.


Treatment: Drugs: bimatoprost /timolol formulation A fixed combination ophthalmic solution
One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.

Treatment: Drugs: bimatoprost/timolol fixed combination ophthalmic solution
One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
Timepoint [1] 0 0
Baseline, Week 12
Primary outcome [2] 0 0
Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2
Timepoint [2] 0 0
Week 2
Primary outcome [3] 0 0
Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6
Timepoint [3] 0 0
Week 6
Primary outcome [4] 0 0
Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
Timepoint [4] 0 0
Week 12
Secondary outcome [1] 0 0
Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12
Timepoint [1] 0 0
Baseline, Week 12
Secondary outcome [2] 0 0
Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12
Timepoint [2] 0 0
Baseline, Week 12

Eligibility
Key inclusion criteria
- Patient has ocular hypertension or glaucoma in both eyes

- Requires IOP-lowering therapy in each eye
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Active or recurrent eye disease that would interfere with interpretation of study data
in either eye

- History of any eye surgery or laser in either eye within 6 months

- Required chronic use of other eye medications during the study

- Anticipated wearing of contact lenses during the study.

- Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2012
Sample size
Target
Accrual to date
Final
561
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
- Sydney
Recruitment postcode(s) [1] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
Czech Republic
State/province [2] 0 0
Brno
Country [3] 0 0
Germany
State/province [3] 0 0
Leipzig
Country [4] 0 0
Hungary
State/province [4] 0 0
Budapest
Country [5] 0 0
Israel
State/province [5] 0 0
Tel Aviv
Country [6] 0 0
Russian Federation
State/province [6] 0 0
Saint-Petersburg
Country [7] 0 0
Spain
State/province [7] 0 0
Valencia
Country [8] 0 0
United Kingdom
State/province [8] 0 0
England

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Allergan
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A
ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once
daily for 12 weeks in patients with glaucoma or ocular hypertension.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01177098
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Allergan
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/ct2/show/NCT01177098